菲律宾批准紧急使用中国科兴疫苗
外电报道,菲律宾在中国科兴生物(SVA.US)60万剂新冠疫苗到境前,批准其紧急使用。菲律宾食品医药品局长Eric Domingo称,科兴疫苗有效防止新冠病毒。由於其对医护人员保护率仅50.4%,科兴不建议向医护人员接种该款疫苗。
菲律宾今年向科兴寻求2,500万剂疫苗,以达成其明年最多70%人口获接种的目标。菲律宾早前已有限度批准使用辉瑞-BioNTech及阿斯利康(AZN.US)疫苗,优先予医护人员接种。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.